XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EPS Calculation (Tables)
 6 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Reconciliation of the (Loss)/Earnings and Shares used in Calculating Basic and Diluted EPS
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the three and six months ended June 30, 2024 and 2023:
 
Three Months Ended
June 30,		Six Months Ended
June 30,
(In Thousands, Except Per Share Amounts)2024202320242023
Basic Earnings/(Loss) per Share:
Net income/(loss)$41,946 $(25,928)$65,159 $46,856 
Dividends declared on preferred stock(8,218)(8,218)(16,437)(16,437)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities(114)— (281)— 
Net income/(loss) available to common stockholders - basic$33,614 $(34,146)$48,441 $30,419 
Basic weighted average common shares outstanding103,446 102,186 103,310 102,170 
Basic Income/(Loss) per Share$0.32 $(0.34)$0.47 $0.30 
Diluted Earnings/(Loss) per Share:
Net income/(loss) available to common stockholders - basic$33,614 $(34,146)$48,441 $30,419 
Interest expense on Convertible Senior Notes — — — — 
Dividends, dividend equivalents and undistributed earnings allocated to participating securities— — — — 
Net income/(loss) available to common stockholders - diluted$33,614 $(34,146)$48,441 $30,419 
Basic weighted average common shares outstanding103,446 102,186 103,310 102,170 
Effect of assumed conversion of Convertible Senior Notes to common shares— — — — 
Unvested and vested restricted stock units1,730 — 1,643 1,771 
Diluted weighted average common shares outstanding (1)
105,176 102,186 104,953 103,941 
Diluted Income/(Loss) per Share$0.32 $(0.34)$0.46 $0.29 
(1)At June 30, 2024, the Company had approximately 341,000 equity instruments outstanding that were excluded from the calculation of diluted EPS for the three and six months ended June 30, 2024, respectively as they were determined to be anti-dilutive.  These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $11.20. These equity instruments may have a dilutive impact on future EPS.